Ably Medical is a Norwegian health technology innovation company with expertise in industrial design, sensor technology, computer science, human factors and organisational psychology. Ably Medical presents the next generation hospital bed that reduces falls, pressure ulcers and nurse load by state-of-the-art innovative use of sensor technology, mechanical design, and machine learning capacity.
The Ably Bed learns, knows, mobilises the patient and collaborates with the medical staff to provide a robust and innovative health care service. Ably Bed is inspired by the professional spirit found among the nursing and medical personnel themselves. The ability of the bed to assist patient movements is modelled from the human spine.
The Ably Medical and MaRS EXCITE study is set to validate the Ably Bed value in hospital settings. The study will document the superiority to standard hospital beds in the market by significantly reduce pressure ulcers, fall and nurse load.
Aegis Medical Innovations
Aegis Medical Innovations Inc. was founded with a mission to commercialize a minimally invasive cardiovascular technology to help prevent strokes in patients with atrial fibrillation (AF). Aegis is working in close partnership with Mayo Clinic to develop a simpler, cheaper and safer percutaneous epicardial procedure for left atrial appendage (LAA) closure called the Sierra Ligations System (Sierra). Following a successful first in human study conducted in 2012, the LASSO-AF clinical study is underway in North America to show the safety and procedural success of the Sierra procedure.
Aegis is confident the results will show that Sierra provides significant advantages over all existing treatments for the patient, physician and payers.
Mild brain injury is very common and accounts for 66-75% of all hospital admissions for head trauma. Most persons with mild TBI generally report a similar pattern of symptoms which include physical, cognitive and emotional/behavioral challenges. Common symptoms following the injury include poor concentration, memory problems, irritability, headaches, fatigue, depression, anxiety, dizziness and increased sensitivity to sound and light (Alves, 1992; Miller, 1993; Slagle 1990). This cluster of symptoms has been estimated to affect 50-80% of individuals within three months after a mild TBI (Mittenberg & Burton, 1994; Long & Novack, 1986). Post-concussive syndrome (PCS) can last from months to years following injury the initial injury (Gouvier et al., 1992). These symptoms are very distressing and often result in difficulties in activities of daily living and/or an inability to return to prior employment. Some people will continue to experience symptoms long after their injury, even if brain scans (i.e., MRIs, CT, EEG) are completely normal. Most studies suggest that approximately 15% of these individuals will continue to report symptoms one year post injury (Satz et al., 1999).
APEXK propose that visual-cognitive dysfunctions and related symptoms caused by mild/blast traumatic brain injury (m/bTBI) induces could be resolved by a specific rehabilitation procedure utilizing APEXK’s device and protocols
The first element of our technology is a software (SIMIAN) that collects different independent visual-cognitive functional parameters through a clinical interface. These parameters are then processed through an intelligent algorithm that generates an integrative visual-cognitive profile called CVCP (characterized visual-cognitive profile), which is used to track patient progression throughout the rehabilitation process. In addition, our software records patient symptomatology. The second element of our technology is a device (CEBUS) that is used both in evaluation and rehabilitation. This platform provides visual and audio stimulations across a person’s visual field, enabling evaluation and oculomotor re-training. The other function of the device is to evaluate/re-train a cognitive reactional field through a complex cognitive reactional task. Through this protocol, it is possible to generate a cognitive reactional mapping representing speed of processing in relation to visual field stimulation, and to generate controlled cognitive overload, allowing concussed patients to be re-introduced to increasing levels of cognitive stimulation.
The EXCITE study will help determine the efficacy and value of APEXK device and protocol for patient with persistent symptoms of concussion.
Assurex Canada helps healthcare providers tailor the right treatment to patients using a genetic test called GeneSight™ , which is displacing the current trial and error approach to prescribing medication for behavioral health conditions.
GeneSight™ technology is based on combinatorial pharmacogenomics (CPGx™), a proprietary informatics platform that integrates and weights the importance of multiple genes that affect an individual’s ability to tolerate and respond to 33 Health Canada approved medications commonly prescribed to treat depression and schizophrenia, as well as anxiety, posttraumatic stress disorder (PTSD), bipolar disorder and other behavioral health conditions.
Within 36 hours of receiving a DNA sample collected with a simple cheek swab, Assurex Canada’s laboratory will send a report to the patient’s healthcare provider that groups medications into the categories of “use as directed,” “use with caution” and “use with increased caution and with more frequent monitoring” based upon a patient’s genetic profile and the genetic pathways through which medications work in the body.
GeneSight™ was developed in the Assurex Health clinical laboratory and is based on patented technology licensed from Mayo Clinic and Cincinnati Children’s Hospital Medical Center. It also incorporates genetic markers discovered by the Centre for Addiction and Mental Health (CAMH). GeneSight™ helps healthcare providers more quickly find an effective treatment for their patients and may save patients from experiencing side effects that often come from taking antidepressants and antipsychotics.
Ondine Biomedical Inc.
Hospital acquired infections such as surgical site infections (SSIs) are the 4th leading cause of death in Canada representing a major risk to patients and a large multi billion dollar cost burden to our healthcare systems. With 40% of hospital acquired infections now multi-drug resistant and the development of new antibiotics are lagging due to the enormous cost and time to market, the risk and costs of surgical site infections are rising. Numerous clinical studies have confirmed that decolonizing the patient’s nose from the harmful pathogens they carry reduces hospital acquired infection rates by 40-60%. The topical antibiotics had been used for nasal decolonization relies on 5 days of patient compliance and quickly generates resistance resulting in most Canadian hospitals not practicing this SSI reduction protocol.
Ondine is the global leader in developing Photodisinfection based non-antibiotic antimicrobial therapies to treat and prevent multi-drug resistant infections. MRSAid, in use at Vancouver General Hospital, has played a major role in the 70% reduction of its surgical site infection rate it has experienced since deploying the pre-surgical nasal Photodisinfection protocol.
The MRSAid study will confirm nasal decolonization speed and efficacy as well as SSI reductions in a randomized blinded study in Ontario facilities.
Alzheimer’s disease (AD) is the most prevalent disorder underlying dementia as well as one of the foremost causes of morbidity and mortality in the aging population. It affects not only those afflicted by the disorder but also places a heavy burden upon their families.
Though a few approved pharmacotherapies do exist for the treatment of AD, these produce symptomatic improvements but are not curative nor have been demonstrated to slow the progression of the disease. Thus, family members of AD patients are faced with the eventual decision of becoming at-home caregivers or relying on long-term care facilities. Home care assistance can help to lengthen the time AD patients are able to remain living in the community, yet a significant number of patients eventually require long-term care facilities. Severe declines in cognition also result in increased accidents and emergency department visits, often resulting in long-term hospitalization.
The Vielight Neuro RX Gamma device is a portable, wearable, low-light level therapy delivery device that administers near-infrared light to the brain trans-cranially and intranasally. The device can be applied by the patient or caregiver at home and does not require specialized training